Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Sell
45
PAVM Quote, Financials, Valuation and Earnings
Last price:
$9.31
Seasonality move
:
21.12%
Day range:
$10.80 - $12.70
52-week range:
$6.00 - $28.44
Dividend yield:
0%
P/E ratio:
0.30x
P/S ratio:
5,129.46x
P/B ratio:
1.20x
Volume:
1.3M
Avg. volume:
1.9M
1-year change:
-37.97%
Market cap:
$10.1M
Revenue:
$3M
EPS (TTM):
-$0.57
Analysts' Opinion
-
Consensus RatingPAVmed, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.50, PAVmed, Inc. has an estimated upside of 2495.63% from its current price of $10.98.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $10.98.
Fair Value
-
According to the consensus of 1 analyst, PAVmed, Inc. has 2495.63% upside to fair value with a price target of $9.50 per share.
PAVM vs. S&P 500
-
Over the past 5 trading days, PAVmed, Inc. has overperformed the S&P 500 by 19.94% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PAVmed, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PAVmed, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter PAVmed, Inc. reported revenues of $5K.
Earnings Growth
-
PAVmed, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter PAVmed, Inc. reported earnings per share of -$0.29.
Enterprise value:
33.6M
EV / Invested capital:
--
Price / LTM sales:
5,129.46x
EV / EBIT:
0.51x
EV / Revenue:
1,159.55x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-9.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.51x
Gross Profit (TTM):
-$307K
Return On Assets:
3.65%
Net Income Margin (TTM):
-1508.12%
Return On Equity:
8.75%
Return On Invested Capital:
4.06%
Operating Margin:
-96880%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.5M | $4M | $29K | $996K | $5K | |
| Gross Profit | -$7.8M | -$4.2M | -$307K | -$623K | -$72K | |
| Operating Income | -$76.9M | -$55.7M | -$20.2M | -$11.6M | -$4.8M | |
| EBITDA | -$73.8M | -$53.8M | -$20M | -$11.3M | -$4.8M | |
| Diluted EPS | -$10.52 | -$4.31 | -$26.94 | $1.44 | -$8.81 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $41.7M | $62M | $32.5M | $2.1M | $4.2M | |
| Total Assets | $43M | $72.5M | $42M | $30.6M | $38.1M | |
| Current Liabilities | $7.8M | $41.9M | $54.5M | $37.6M | $10.5M | |
| Total Liabilities | $7.8M | $43.9M | $57.8M | $39.9M | $12.3M | |
| Total Equity | $35.2M | $28.6M | -$15.8M | -$9.4M | $25.8M | |
| Total Debt | -- | $37.5M | $48.3M | $34.4M | $8.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$57M | -$45.5M | -$3.6M | -$8.9M | -$896K | |
| Cash From Investing | $643K | -$16.4M | -$21K | -$16.1M | -$3K | |
| Cash From Financing | $26M | $36.2M | $5.9M | $284K | -$2K | |
| Free Cash Flow | -$57.3M | -$45.8M | -$3.6M | -$8.9M | -$899K | |
PAVM
Sector
Market Cap
$10.1M
$26M
Price % of 52-Week High
38.61%
51.81%
Dividend Yield
0%
0%
Shareholder Yield
21.36%
-1.66%
1-Year Price Total Return
-37.97%
-18.29%
Beta (5-Year)
1.106
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.77
200-day SMA
Sell
Level
$14.84
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$8.18
Relative Strength Index (RSI14)
Buy
Level
58.99
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-77.8075
50-day SMA
Buy
Level
$9.42
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-17.4708)
Sell
CA Score
(Annual)
Level (-13.0682)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.7467)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, PAVM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PAVM average analyst price target in the past 3 months is $9.50.
-
Where Will PAVmed, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that PAVmed, Inc. share price will rise to $9.50 per share over the next 12 months.
-
What Do Analysts Say About PAVmed, Inc.?
Analysts are divided on their view about PAVmed, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PAVmed, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is PAVmed, Inc.'s Price Target?
The price target for PAVmed, Inc. over the next 1-year time period is forecast to be $9.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PAVM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PAVmed, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of PAVM?
You can purchase shares of PAVmed, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PAVmed, Inc. shares.
-
What Is The PAVmed, Inc. Share Price Today?
PAVmed, Inc. was last trading at $9.31 per share. This represents the most recent stock quote for PAVmed, Inc.. Yesterday, PAVmed, Inc. closed at $10.98 per share.
-
How To Buy PAVmed, Inc. Stock Online?
In order to purchase PAVmed, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PAVM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PAVM
Sector
P/E ratio
0.30x
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
1.20x
1.83x
Price / LTM sales
5,129.46x
1.56x
Growth Metrics
PAVM
Sector
Revenue growth
-99.5%
4.18%
Earnings growth
-120.38%
9.66%
Revenue (5-year growth)
--
6.28%
Earnings forecast
-$4.50
-$0.18
Profitability
PAVM
Sector
Profitability FY 2024
-$3M
$3.1M
Return on invested capital
4.06%
-32.89%
Return on assets
3.65%
-29.56%
Return on equity
8.75%
-38.66%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
12
Balance Sheet
PAVM
Sector
Total cash
$3.1M
$25.2M
Short term investments
--
$25.1M
Total assets
$30.7M
$73M
Long term debt
$8.7M
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
69
INTC alert for Jan 23
Intel Corp. [INTC] is down 17.01% over the past day.
Buy
70
BNR alert for Jan 23
Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.
Buy
80
MTRN alert for Jan 23
Materion Corp. [MTRN] is down 9.13% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
